Investor Presentaiton
Investor presentation
First three months of 2017
Slide 108
Higher profitability in the biopharmaceuticals segment
driven by lower COGS and S&D
Diabetes & Obesity P&L - full year 2016
DKK
billion
100
Biopharmaceuticals P&L – full year 2016
DKK
billion
30
-15%
80
-28%
60
40
20
24
-12%
-17%
-13%
-4% +1%
54%
18
-12%
-3%
+1% 42%
12
0
Sales
COGS S&D
R&D Admin ΟΟΙ
OP
6
Sales
COGS
S&D R&D Admin OOI
OP
P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit
S&D: Sales and distribution cost; R&D: research and development cost; Admin: administrative cost
P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit
S&D: Sales and distribution cost; R&D: research and development cost; Admin: administrative cost
changing
diabetes®
novo nordiskView entire presentation